KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Travere Therapeutics (TVTX) over the last 16 years, with Q4 2024 value amounting to $4000.0.

  • Travere Therapeutics' Net Income towards Common Stockholders rose 10025.36% to $4000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was $4000.0, marking a year-over-year increase of 10015.77%. This contributed to the annual value of -$915000.0 for FY2024, which is 10034.54% down from last year.
  • Per Travere Therapeutics' latest filing, its Net Income towards Common Stockholders stood at $4000.0 for Q4 2024, which was up 10025.36% from -$100000.0 recorded in Q3 2024.
  • Travere Therapeutics' 5-year Net Income towards Common Stockholders high stood at $240.0 million for Q3 2023, and its period low was -$121.6 million during Q4 2020.
  • Its 5-year average for Net Income towards Common Stockholders is -$3.5 million, with a median of -$101500.0 in 2024.
  • In the last 5 years, Travere Therapeutics' Net Income towards Common Stockholders plummeted by 657439.9% in 2021 and then surged by 156569.03% in 2023.
  • Quarter analysis of 5 years shows Travere Therapeutics' Net Income towards Common Stockholders stood at -$121.6 million in 2020, then grew by 27.01% to -$88.8 million in 2021, then soared by 122.32% to $19.8 million in 2022, then tumbled by 107.96% to -$1.6 million in 2023, then soared by 100.25% to $4000.0 in 2024.
  • Its Net Income towards Common Stockholders was $4000.0 in Q4 2024, compared to -$100000.0 in Q3 2024 and -$757000.0 in Q2 2024.